Clinical Trials
Braintumor Website

These trials were the most recently added or updated

NCT Trial Name# of CentersLast Updated

NCT02858869

  Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
110/20/2016

NCT02639325

  Tumor Related Epilepsy
110/20/2016

NCT02388659

  Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas
110/20/2016

NCT02186262

  Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas
110/20/2016

NCT02155452

  Fluorescence and Glioma Heterogeneity
110/20/2016

NCT02150564

  3D Ultra Sound for Resection of Brain Tumors
110/20/2016

NCT01811992

  Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma
110/20/2016

NCT02941302

  Multimodality Imaging Combined With Multiple Targets Pathological Examination for Detecting of Biological Borders of Gliomas: a Clinical Application Study
110/19/2016

NCT02796261

  Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
1510/19/2016

NCT02731521

  Clinical Development of MR Spectroscopy and Imaging in Brain Cancers
110/19/2016

NCT02510950

  Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
110/19/2016

NCT02419664

  Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
110/19/2016

NCT02186509

  Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
110/19/2016

NCT02095132

  WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
410/19/2016

NCT01907165

  Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide
110/19/2016

NCT01898130

  Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
210/19/2016

NCT01873469

  Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme
110/19/2016

NCT02939378

  Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study
110/18/2016

NCT02414165

  P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA
5510/18/2016

NCT02363933

  Perampanel in Seizure Patients With Primary Glial Brain Tumors
110/18/2016

NCT02100891

  Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors
210/18/2016

NCT01601184

  Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
610/18/2016

NCT02937844

  Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
110/17/2016

NCT02614794

  Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
4210/17/2016

NCT01892397

  Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
710/17/2016

NCT01421524

  Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
2510/17/2016

NCT01305941

  A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
110/17/2016

NCT02180217

  Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
7010/16/2016

NCT02329795

  Image-derived Prediction of Response to Chemo-radiation in Glioblastoma
110/14/2016

NCT00736749

  Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
14110/14/2016

NCT02896504

  Chemotherapy Effect on Brain Structure, Neurophysiology and Psychomotor Behavior in Breast Cancer Patients
110/13/2016

NCT02546102

  Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
6210/13/2016

NCT02392078

  Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
1010/13/2016

NCT02227576

  Prevention of Thrombocytopenia in Glioblastoma Patients
410/13/2016

NCT00001595

  An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
110/13/2016

NCT02933736

  Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
110/12/2016

NCT02728349

  Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma
110/12/2016

NCT02709889

  Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
510/12/2016

NCT02659800

  IL-7 in Increasing Low CD4 Counts After Concurrent Radiation and Temozolomide Treatment in Patients With High Grade Gliomas
310/12/2016

NCT02658981

  Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma
1010/12/2016

NCT02650401

  Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors
610/12/2016

NCT02568267

  Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
8010/12/2016

NCT02420613

  Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG)
110/12/2016

NCT01622868

  Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
9810/12/2016

NCT01459237

  Effects of Hormone Stimulation on Brain Scans for Cushing s Disease
110/12/2016

NCT02909777

  Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
110/11/2016

NCT02903069

  Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
110/11/2016

NCT02764151

  First in Patient Study for PF-06840003 in Malignant Gliomas
510/11/2016

NCT02478164

  Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
210/11/2016

NCT02336451

  A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
5410/11/2016



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2016 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites